

07.12.2022

13:10 - 13:50 **Type: Opening session** **Hall B**
Title: Welcome to the ESMO Immuno-Oncology Congress 2022 and Awards

13:10 - 13:50 **Programme to be announced**

14:05 - 15:05 **Type: Controversy** **Hall A**
Title: Cancer vaccines: promise or dead end?

14:05 - 14:15 **Introduction and first vote**
L. Butterfield, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

14:15 - 14:35 **Yes**

14:35 - 14:55 **No**

14:55 - 15:05 **Second vote and conclusions**
L. Butterfield, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

14:05 - 15:35 **Type: Educational** **Hall B**
Title: Local therapy for systemic beneficial goals
Moderation: Aurélien Marabelle, FR

14:05 - 14:25 **Intratumoral tumor-specific treg depletion**
A. Marabelle, Institut Gustave Roussy, Villejuif, FR

14:25 - 14:45 **Intratumoural STING agonists**
E. Parkes, University of Oxford, Oxford, GB

14:45 - 15:05 **Intratumoural oncolytic virotherapy**
S. Champiat, Institut Gustave Roussy, Villejuif, Cedex, FR

15:05 - 15:25 **Focal tumour radiotherapy as a trigger for systemic immune response**
S. Demaria, Weill Cornell Medical College, New York, US

15:25 - 15:35 **Q&A**

14:05 - 15:35	Type: Educational Title: The future of CNS tumors: Learning from failures and driven by biology Moderation: Anna Di Giacomo, IT	Hall C
14:05 - 14:25	Successes, pitfalls, and failures: A clinical perspective <u>A. Di Giacomo</u> , AOU Senese - Santa Maria delle Scotte, Siena, IT	
14:25 - 14:45	The integrated genomic and epigenomic landscape of brain tumours	
14:45 - 15:05	The immune microenvironment of primary and metastatic brain tumours <u>A. Anichini</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
15:05 - 15:25	Future perspectives on brain tumours' treatment <u>M. Weller</u> , USZ - Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH	
15:25 - 15:35	Q&A	
15:35 - 16:00	Type: Break Title: Coffee break	Foyer ABC
16:00 - 17:30	Type: Proffered Paper session Title: Proffered Paper session 1	Hall A
16:00 - 17:30	Type: Educational Title: Predictive factors for T cell therapy Moderation: Alan Melcher, GB	Hall B
16:00 - 16:20	The dynamics of T cell receptor signalling in cancer immunotherapy <u>A. Melcher</u> , ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB	
16:20 - 16:40	The role of the vasculature on lymphocyte infiltration into solid tumours <u>A. Gallimore</u> , Cardiff University - School of Medicine, Cardiff, GB	
16:40 - 17:00	Radiotherapy and T cell infiltration into tumours <u>F. Herrera</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
17:00 - 17:20	T cells in clinical immunotherapy for gynaecological cancers	
17:20 - 17:30	Q&A	

16:00 - 17:30	Type: Educational Title: Thoracic tumours	Hall C
16:00 - 16:20	Immune dynamics during lung cancer development, from premalignant to invasive <u>J. Reading</u> , UCL Cancer Institute - Paul O'Gorman Building, London, GB	
16:20 - 16:40	Building on CAR-T experience in mesothelioma <u>P. Adusumilli</u> , Memorial Sloan Kettering Cancer Center, New York, US	
16:40 - 17:00	Lecture title to be announced <u>N. Girard</u> , Institut Curie, Paris, FR	
17:00 - 17:20	Beyond PD(L)1 in thoracic tumors: Novel targets and combinations <u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
17:20 - 17:30	Q&A	
17:45 - 18:45	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 1	Hall A

08.12.2022

09:00 - 10:30 **Type: Educational** **Hall A**
Title: Novel clinical and translational insights in melanoma

09:00 - 09:20 **Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma**

S. Vagner, Institut Gustave Roussy, Villejuif, Cedex, FR

09:20 - 09:40 **Melanoma and Ag-targeting**

09:40 - 10:00 **Single-cell analysis reveals new evolutionary complexity in uveal melanoma**

10:00 - 10:20 **Novel therapeutic immunotherapy modalities in cutaneous melanoma**

M. Mandala, Università degli Studi di Perugia, Perugia, IT

10:20 - 10:30 **Q&A**

09:00 - 10:30 **Type: Educational** **Hall B**
Title: Imaging biomarkers in IO for cancer
Moderation: E.G. Elisabeth de Vries, NL

09:00 - 09:20 **AI and radiomics: Results in immunotherapy**

L. Derclé, Columbia University, New York, US

09:20 - 09:40 **MRI techniques to visualise what is happening during immunotherapy**

A.H.D. Lau, University of Oxford, Oxford, GB

09:40 - 10:00 **Whole body imaging macrophages**

10:00 - 10:20 **Molecular imaging of immunotherapy and CD8**

E.G.E. De Vries, UMCG - University Medical Center Groningen, Groningen, NL

10:20 - 10:30 **Q&A**

09:00 - 10:30 **Type: Mini Oral session** **Hall C**
Title: Mini Oral session 1

10:30 - 11:00 **Type: Break** **Foyer ABC**
Title: Coffee break

11:00 - 12:30 **Type: Educational** **Hall A**
Title: H&N cancers
Moderation: Kevin Harrington, GB

- 11:00 - 11:20 **Lessons from neoadjuvant use of immunotherapy before curative-intent surgery**
- 11:20 - 11:40 **Lessons from trials of curative-intent (chemo)radiotherapy combined with immunotherapy**
- 11:40 - 12:00 **Lessons from trials of systemic immunotherapies in relapsed and/or metastatic disease**
- 12:00 - 12:20 **Lessons from novel intra-tumoural therapies in head and neck cancer**
K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB
- 12:20 - 12:30 **Q&A**

11:00 - 12:30 **Type: Educational** **Hall B**
Title: B cells as a therapeutic opportunity
Moderation: Tullia Bruno, US

- 11:00 - 11:20 **B cell function within tertiary lymphoid structures**
T. Bruno, UPMC Hillman Cancer Center, Pittsburgh, US
- 11:20 - 11:40 **Tertiary lymphoid structure formation in non-small cell lung cancer**
M.-C. Dieu-Nosjean, Institut national de la santé et de la recherche médicale, Paris, FR
- 11:40 - 12:00 **Antibody responses in the TME**
Z. Shulman, Weizmann Institute of Science, Rehovot, IL
- 12:00 - 12:20 **Regulatory B cells in cancer**
C. Mauri, UCL Cancer Institute - UCL - London's Global University, London, GB
- 12:20 - 12:30 **Q&A**

11:00 - 12:30	Type: Educational Title: Tumour microenvironment	Hall C
11:00 - 11:20	Cancer-associated fibroblasts biological and spatial heterogeneity	
11:20 - 11:40	Oncolytic viruses and the tumour microenvironment	
11:40 - 12:00	The role of the tumour microenvironment in oncolytic virotherapy for myeloma <u>F. Errington-Mais</u> , UL - University of Leeds, Leeds, GB	
12:00 - 12:20	Tumour-associated macrophages in breast cancer	
12:20 - 12:30	Q&A	
12:30 - 13:15	Type: Poster Display Title: Poster Display	Foyer ABC
13:15 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 2	Hall A
13:15 - 14:00	Type: Young Oncologists (YO) session Title: YO Vesalius talk	Foyer
13:15 - 14:00	Programme to be announced	
14:30 - 15:30	Type: Controversy Title: Combination of radiotherapy and immunotherapy is a good idea	Hall A
14:30 - 14:40	Introduction and first vote	
14:40 - 15:00	Yes	
15:00 - 15:20	No	
15:20 - 15:30	Second vote and conclusions	

14:30 - 15:30	Type: Mini Oral session Title: Mini Oral session 2	Hall B
15:30 - 16:00	Type: Break Title: Coffee break	Foyer ABC
16:00 - 17:30	Type: Educational Title: GU malignancies Moderation: Laurence Albiges, FR	Hall A

16:00 - 16:25 **IO in renal cell carcinoma: The latest on combining and sequencing**
L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

16:25 - 16:50 **Prostate cancer immunotherapy**
L. Fong, UCSF Diabetes Teaching Center, San Francisco, US

16:50 - 17:15 **Bladder cancer immunotherapy**
A. Wilkins, Francis Crick Institute, London, GB

17:15 - 17:30 **Q&A**

16:00 - 17:30	Type: Educational Title: Tumour and immunometabolism	Hall B
----------------------	---	---------------

16:00 - 16:20 **Immunometabolism of dendritic cells**

16:20 - 16:40 **Obesity and immune response to cancer**
L. Dyck, MDC - Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin-Buch, DE

16:40 - 17:00 **Connecting mitochondrial metabolism and function of myeloid cells**
D. Sancho, CNIC - Centro Nacional de Investigaciones Cardiovasculares, Madrid, ES

17:00 - 17:20 **Microbiota and nutrition to module I-O efficacy**
L. Zitvogel, Institut Gustave Roussy, Villejuif, Cedex, FR

17:20 - 17:30 **Q&A**

16:00 - 17:30	Type: Educational Title: Pharma pipeline session	Hall C
17:45 - 18:45	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 3	Hall A

09.12.2022

09:00 - 10:30 **Type: Educational** **Hall A**
Title: GI tumours
Moderation: Marco Gerlinger, GB

09:00 - 09:20 **Signals and rational development opportunities for immunotherapy in MMR proficient colorectal cancer**
M. Gerlinger, ICR - Institute of Cancer Research, London, GB

09:20 - 09:40 **Response and resistance in MMR deficient colorectal cancer: Insights from mouse and man**
A. Bardelli, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT

09:40 - 10:00 **New IO combinations and biomarkers in oesophageal and gastric cancers**
I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

10:00 - 10:20 **Advancing immunotherapy in hepatocellular carcinoma through rational combinations and biomarkers**
L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT

10:20 - 10:30 **Q&A**

09:00 - 10:30 **Type: Educational** **Hall B**
Title: Shared and neoantigen vaccines and T cells
Moderation: Lisa Butterfield, US; Sine Reker Hadrup, DK

09:00 - 09:25 **Neoantigen reactive T cells plays a critical role in immunotherapy**
S. Reker Hadrup, DTU - Technical University of Denmark - DTU Health Tech, Kongens Lyngby, DK

09:25 - 09:50 **Lessons learned from dendritic cell vaccines**
L. Butterfield, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

09:50 - 10:15 **New neoantigen perspectives**
S. Quezada, University College London, London, GB

10:15 - 10:30 **Q&A**

09:00 - 10:30 **Type: Educational** **Hall C**
Title: Epigenetic immunomodelling

10:30 - 11:00	Type: Break Title: Coffee break	Foyer ABC
11:00 - 12:30	Type: Educational Title: Haematological malignancies Moderation: Monalisa Ghosh, US	Hall A
11:00 - 11:20	Improving outcomes of cellular therapy in non-Hodgkin's B-cell lymphoma <u>M. Ghosh</u> , Michigan Medicine University of Michigan, Ann Arbor, US	
11:20 - 11:40	Oncolytic virus therapy: A novel immunotherapeutic approach in haematologic malignancies	
11:40 - 12:00	Choosing immunotherapy for multiple myeloma: Bi-specific antibodies, chimeric antigen receptor T-cells, antibody-drug conjugates, or all of the above?	
12:00 - 12:20	Finding the optimal immunotherapeutic targets in acute myeloid leukemia	
12:20 - 12:30	Q&A	
11:00 - 12:30	Type: Educational Title: Proffered Paper session 2	Hall B
11:00 - 12:30	Type: Educational Title: Innate immune effectors	Hall C
11:00 - 11:25	Lecture title to be announced	
11:25 - 11:50	Deciphering how and why NK cells are altered within the tumour microenvironment' <u>D. Withers</u> , The University of Birmingham - Institute for Cancer Studies, Birmingham, GB	
11:50 - 12:15	Diversity, function and clinical significance of tumor-associated macrophages <u>A. Mantovani</u> , Humanitas University, Milan, IT	
12:15 - 12:30	Q&A	
12:30 - 13:15	Type: Break Title: Lunch	Foyer ABC

12:30 - 13:15	Type: Young Oncologists (YO) session Title: YO Mentorships	Foyer
12:30 - 13:15	Programme to be announced	
13:15 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 4	Hall A
14:30 - 16:00	Type: Educational Title: Gynaecological malignancies and breast tumours Moderation: George Coukos, CH	Hall A
14:30 - 14:50	Leveraging antitumor immunity: Lessons from ovarian cancer <u>G. Coukos</u> , UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH	
14:50 - 15:10	TIL therapy of ovarian cancer	
15:10 - 15:30	Breast cancer immunotherapy	
15:30 - 15:50	Response to PD-L1 blockade in triple-negative breast cancer: Lessons from the tumour microenvironment	
15:50 - 16:00	Q&A	
14:30 - 16:00	Type: Educational Title: Emerging bi-/multi-specific antibody/antibody-like platforms	Hall B